Reference
Joshi M, et al. Long-Term Cost-Effectiveness of Nadofaragene Firadenovec and Oportuzumab Monatox for Treatment of Bacillus Calmette-Guerin (BCG)-Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC). 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN74, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3339/109528
Rights and permissions
About this article
Cite this article
Finding new cost-effective treatment options for BCG-unresponsive bladder cancer. PharmacoEcon Outcomes News 880, 11 (2021). https://doi.org/10.1007/s40274-021-7769-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7769-x